Bone marrow transplantation from a human leukocyte antigen-mismatched unrelated donor in a case with C1q deficiency associated with refractory systemic lupus erythematosus.
Risa MatsumuraShinji MochizukiNatsuki MaruyamaYusuke MorishitaHiroshi KawaguchiSatoshi OkadaMiyuki TsumuraShunsaku KajiJunya ShimizuAkira ShimadaMasao KobayashiPublished in: International journal of hematology (2020)
Human C1q deficiency is frequently associated with systemic lupus erythematosus (SLE), which requires long-term systemic corticosteroid administration. We report the case of a 12-year-old female patient with C1q deficiency presenting with intractable SLE who successfully underwent bone marrow transplantation from a human leukocyte antigen (HLA)-mismatched unrelated donor with an immunosuppressive conditioning regimen based on fludarabine, melphalan, and anti-thymocyte globulin. She developed Grade I graft-versus-host disease, but did not have any transplantation-related morbidity. Complete donor chimerism has been maintained for 2 years after transplantation, leading to the restoration of C1q levels and the resolution of SLE symptoms. Normal C1q mRNA expression was observed in CD14 + cells. Hematopoietic stem cell transplantation from an HLA-mismatched donor is a feasible treatment for patients with C1q deficiency with refractory SLE that is dependent on systemic corticosteroid treatment who do not have an HLA-matched donor.
Keyphrases
- systemic lupus erythematosus
- disease activity
- bone marrow
- endothelial cells
- replacement therapy
- induced pluripotent stem cells
- pluripotent stem cells
- induced apoptosis
- stem cells
- combination therapy
- acute myeloid leukemia
- low dose
- signaling pathway
- cell cycle arrest
- cord blood
- cell death
- physical activity
- single molecule
- drug induced
- allogeneic hematopoietic stem cell transplantation